As healthcare spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important. This research brief shares novel, groundbreaking studies that have helped define the value of new oncology drugs, and recommends new criteria for framing value in cancer care.
